Molecular docking, structure–activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani | Zendy

Jaspreet Kaur | Zendy; Shyam Sundar | Zendy; Neeloo Singh | Zendy

Open Access

Molecular docking, structure–activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani

Author(s) -

Jaspreet Kaur,

Shyam Sundar,

Neeloo Singh

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq189

Subject(s) - leishmania donovani , amastigote , pharmacology , biology , biochemistry , leishmania , leishmaniasis , visceral leishmaniasis , immunology , parasite hosting , world wide web , computer science

Using the pteridine reductase (PTR1) enzyme of Leishmania as the target, the objective of our study was to find a drug candidate that can enter the clinical development process after being evaluated for safety and efficacy in animals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research